Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
25.2M
-
Shares change
-
-3.46M
-
Total reported value, excl. options
-
$51.8M
-
Value change
-
-$9.7M
-
Put/Call ratio
-
0.14
-
Number of buys
-
48
-
Number of sells
-
-49
-
Price
-
$2.06
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2025
140 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q3 2025.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.2M shares
of 66.6M outstanding shares and own 37.78% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (3.99M shares), VANGUARD GROUP INC (3.59M shares), Laurion Capital Management LP (2.47M shares), Pfizer Inc (2.41M shares), BLAIR WILLIAM & CO/IL (2.21M shares), ACORN CAPITAL ADVISORS, LLC (1.96M shares), GEODE CAPITAL MANAGEMENT, LLC (1.54M shares), STATE STREET CORP (1.15M shares), FLPUTNAM INVESTMENT MANAGEMENT CO (597K shares), and NORTHERN TRUST CORP (520K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.